Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
LUMRY, W
15  Ergebnisse:
OpenAccess-Volltexte X
Personensuche X
?
1

The international WAO/EAACI guideline for the management of..:

Maurer, Marcus ; Magerl, Markus ; Betschel, S...
World Allergy Organization journal.  , 2022
Link: https://publica.fraunhof..
 
?
2

Long-Term Outcomes with Subcutaneous C1-Inhibitor Replaceme..:

Craig T ; Zuraw B ; Longhurst H...
info:eu-repo/semantics/altIdentifier/pmid/30772477.  , 2019
Link: http://hdl.handle.net/24..
 
?
3

Long-Term Outcomes with Subcutaneous C1-Inhibitor Replaceme..:

Craig, T ; Zuraw, B ; Longhurst, H...
https://discovery.ucl.ac.uk/id/eprint/10089106/1/1-s2.0-S2213219819301631-main.pdf.  , 2019
Link: https://discovery.ucl.ac..
 
?
4

Treatment effect of switching from intravenous to subcutane..:

Craig T ; Lumry W ; Cicardi M...
info:eu-repo/semantics/altIdentifier/pmid/30660873.  , 2019
Link: http://hdl.handle.net/24..
 
?
5

Evaluation of avoralstat, an oral kallikrein inhibitor, in ..:

Riedl, M. A ; Aygören‐Pürsün, E ; Baker, J...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175137/.  , 2018
Link: http://www.ncbi.nlm.nih...
 
?
6

International consensus on the diagnosis and management of ..:

Farkas, H ; Martinez-Saguer, I ; Bork, K...
Allergy--0105-4538--1398-9995 Vol. 72 Issue. 2 No. pp: 300-313.  , 2017
Link: https://doi.org/10.1111/..
 
?
7

Inhibiting plasma kallikrein for hereditary angioedema prop..:

Banerji, A ; Busse, P ; Shennak, M...
info:eu-repo/semantics/altIdentifier/pmid/28225674.  , 2017
Link: http://hdl.handle.net/24..
 
?
8

Icatibant for laryngeal hereditary angioedema (HAE) attacks:

Bas, M ; Greve, J ; Strassen, U...
http://dx.doi.org/10.3205/14hnod005.  , 2014
Link: https://doi.org/10.3205/..
 
?
9

The international WAO/EAACI guideline for the management of..:

Maurer, Marcus ; Magerl, Markus ; Betschel, S...
Allergy. European journal of allergy and clinical immunology.  , 2022
Link: https://publica.fraunhof..
 
?
10

Population pharmacokinetics of subcutaneous C1-inhibitor fo..:

Pawaskar D ; Tortorici M. A ; Zuraw B...
info:eu-repo/semantics/altIdentifier/pmid/29998524.  , 2018
Link: http://hdl.handle.net/24..
 
?
11

Effect of Lanadelumab Compared with Placebo on Prevention o..:

Banerji A ; Riedl M. A ; Bernstein J. A...
info:eu-repo/semantics/altIdentifier/pmid/30480729.  , 2018
Link: http://hdl.handle.net/24..
 
?
12

Clinical Usage of a C1 Esterase Inhibitor Concentrate for H..:

Baker, J. W ; Bygum, A ; Busse, P. J...
Baker , J W , Bygum , A , Busse , P J , Edelman , J M , Lumry , W R , Machnig , T , Martinez-Saguer , I & Rojavin , M 2015 , ' Clinical Usage of a C1 Esterase Inhibitor Concentrate for Hereditary Angioedema : Final Results from a Large International Registry ' , Journal of Allergy and Clinical Immunology , vol. 135 , no. 2 Supplement , 623 , pp. AB192 . https://doi.org/10.1016/j.jaci.2014.12.1564.  , 2015
Link: https://portal.findresea..
 
?
13

Gefapixant, a P2X3 receptor antagonist, for the treatment o..:

Smith, Jaclyn A ; Kitt, Michael M ; Morice, Alyn...
https://hull-repository.worktribe.com/output/3351486.  , 2020
Link: https://hull-repository...
 
?
14

Definition, aims, and implementation of GA2LEN/HAEi Angioed..:

Maurer, M. (Marcus) ; Aberer, W. (W.) ; Agondi, R. (Rosana)...
http://repub.eur.nl/pub/126689.  , 2020
Link: http://repub.eur.nl/pub/..
 
?
15

Efficacy and Safety of an Intravenous C1-Inhibitor Concentr..:

Timothy Craig D.O ; Ralph Shapiro M.D ; Arthur Vegh M.D...
https://doi.org/10.2500/ar.2017.8.0192.  , 2017
Link: https://doi.org/10.2500/..
 
1-15